Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue.
BAT
BCAAs
BCKAs
GIPR
GLP-1R
Tirzepatide
Journal
Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
16
06
2022
revised:
12
07
2022
accepted:
13
07
2022
pubmed:
4
8
2022
medline:
15
9
2022
entrez:
3
8
2022
Statut:
ppublish
Résumé
Tirzepatide, a dual GIP and GLP-1 receptor agonist, delivered superior glycemic control and weight loss compared to selective GLP-1 receptor (GLP-1R) agonism in patients with type 2 diabetes (T2D). These results have fueled mechanistic studies focused on understanding how tirzepatide achieves its therapeutic efficacy. Recently, we found that treatment with tirzepatide improves insulin sensitivity in humans with T2D and obese mice in concert with a reduction in circulating levels of branched-chain amino (BCAAs) and keto (BCKAs) acids, metabolites associated with development of systemic insulin resistance (IR) and T2D. Importantly, these systemic effects were found to be coupled to increased expression of BCAA catabolic genes in thermogenic brown adipose tissue (BAT) in mice. These findings led us to hypothesize that tirzepatide may lower circulating BCAAs/BCKAs by promoting their catabolism in BAT. To address this question, we utilized a murine model of diet-induced obesity and employed stable-isotope tracer studies in combination with metabolomic analyses in BAT and other tissues. Treatment with tirzepatide stimulated catabolism of BCAAs/BCKAs in BAT, as demonstrated by increased labeling of BCKA-derived metabolites, and increases in levels of byproducts of BCAA breakdown, including glutamate, alanine, and 3-hydroxyisobutyric acid (3-HIB). Further, chronic administration of tirzepatide increased levels of multiple amino acids in BAT that have previously been shown to be elevated in response to cold exposure. Finally, chronic treatment with tirzepatide led to a substantial increase in several TCA cycle intermediates (α-ketoglutarate, fumarate, and malate) in BAT. These findings suggest that tirzepatide induces a thermogenic-like amino acid profile in BAT, an effect that may account for reduced systemic levels of BCAAs in obese IR mice.
Identifiants
pubmed: 35921984
pii: S2212-8778(22)00119-3
doi: 10.1016/j.molmet.2022.101550
pmc: PMC9396640
pii:
doi:
Substances chimiques
Amino Acids, Branched-Chain
0
Glucagon-Like Peptide-1 Receptor
0
Gastric Inhibitory Polypeptide
59392-49-3
tirzepatide
OYN3CCI6QE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101550Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier GmbH.. All rights reserved.